<DOC>
	<DOCNO>NCT02508350</DOCNO>
	<brief_summary>The first objective study characterize pharmacokinetics pharmacodynamics daptomycin daily dose 12mg/kg septic shock patient ; second objective identify optimal dose scheme daptomycin among patient septic shock enhance therapeutic outcome .</brief_summary>
	<brief_title>The Pharmacokinetics/Pharmacodynamics High-dose Daptomycin Patients With Septic Shock</brief_title>
	<detailed_description>Daptomycin novel lipopeptide exhibit concentration-dependent bactericidal activity multidrug-resistant Gram-positive pathogen , include Methicillin-resistant Staphylococcus aureus ( MRSA ) . In recent year , daptomycin play important role treatment septic shock . The pharmacokinetics daptomycin significant change patient septic shock , prove recent dosage regiment come low blood drug concentration unsatisfactory outcome . Although high-dose daptomycin show safety effectiveness treatment critically ill patient , still pharmacokinetics pharmacodynamics data scant . So purposes study characterize pharmacokinetics pharmacodynamics daptomycin daily dose 12mg/kg septic shock patient ; second objective identify optimal dose scheme daptomycin among patient septic shock enhance therapeutic outcome .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>≥18 year ≤75 year confirm suspected bloodstream soft tissue infection cause grampositive organism know hypersensitivity daptomycin product excipients document suspected pneumonia cause grampositive organism infection daptomycinresistant organism presence history rhabdomyolysis sign symptom myopathy elevation creatine phosphokinase concentration 6.pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>